| INTRODUCTION
Asthma is a chronic inflammatory disease where several structural changes decrease airflow and gas exchange. These changes include -but are not limited to-increased smooth muscle mass, increased vascularity, epithelial dysfunction and a notably altered extracellular matrix (ECM) composition (reviewed in 1-2). The ECM is comprised of several classes of proteins to maintain integrity and balance between the elasticity and rigidity of the lung tissue. In adult asthma, collagens I, V, fibronectin and tenascin are increased 3 and col IV and elastin are decreased. 4 We recently found that the noncollagenous domain-1 of col IV α3 (tumstatin) is markedly reduced in adult asthmatic lung tissue compared with nonasthmatics. 5 Col IV is a major ECM protein, and it exists as six genetically distinct isoforms. 6, 7 Its fibrils are not only found throughout the lung but also in the basal membrane of blood vessels and the epithelium. 5, 8 Treatment of an experimental asthma mouse model with recombinant tumstatin resulted in a significant amelioration of bronchial hyperresponsiveness, infiltration with inflammatory cells, decreased vascular remodelling and reduced mucus production, 5 which was recently confirmed by a segmental allergen challenge model in a chronic house dust mite sheep model. 9 Additionally, Harkness et al 10 identified that tumstatin may also play an important role in the control of neutrophil inflammation. ECM fragments, which act independently of the parent molecule, are collectively assigned to a class of molecules termed matrikines. Matrikines in the lung are innumerous and serve several functions (reviewed in [11] [12] [13] [14] . The role of Col IV matrikines in neutrophilic inflammation (e.g., exacerbation in asthma), especially a novel active region in tumstatin 15 however, has not been investigated to date.
Neutrophilic inflammation in asthma occurs independent of infection and is a recognized phenotype of asthma (reviewed in 16).
The lack of response to therapeutics such as corticosteroids or β2-agonists 17 is typically associated with neutrophils in sputum or bronchoalveolar lavage samples. 18, 19 Severe adult asthma phenotypes are very stable, 20 and Haldar and colleagues identified two groups dominated by neutrophilic inflammation in secondary care refractory adult asthmatics. 21 A subgroup of these donors (11.7% of all donors tested) with high symptom expression had the highest frequency of
severe exacerbations of all phenotypes tested (5.43 events per year). 21 As a result, uncontrolled adult asthmatics are more likely to be hospitalized (severe exacerbations) and incur half of the costs associated with asthma therapy. 22 In addition, decreasing lung function and increasing lung tissue remodelling are found in these asthmatics. Asthma exacerbations are often a result of viral infections, most notably inducers of the common cold (Rhinovirus) and flu (Influenza strains). 23, 24 This study sought to investigate the role of a novel active region within tumstatin (CP17) and its implication in neutrophil inflammatory responses related to asthma exacerbation.
| METHODS

| Donor population
Blood from voluntary healthy donors (mean age 33.8 years) was taken via cubital venipuncture. Current infection was excluded by questionnaire and temperature measurement. Written informed consent was obtained from all participants, and the study design was approved by the local Ethics Committee of the University of Lübeck, Germany (AZ 11-044; Table 1 ).
| Neutrophil isolation
Venous blood samples (cubital venipuncture) were treated with Lithium-Heparin and stored at room temperature (20°C) and processed within 1 hour. Granulocytes were isolated by density gradient centrifugation using Ficoll (PAA, Coelbe, Germany). Centrifugation was performed with 400 rcf (relative centrifugal force) for 30 minutes at 8°C (Centrifuge 5810R, Eppendorf AG, Hamburg, Germany).
Erythrocytes were lysed with pyrogen-free aqua bidest for 45 seconds, and lysis was stopped with 10× PBS. Granulocyte collection was performed by centrifugation with 300 rcf for 10 minutes at 8°C.
The final cell pellet was resuspended in human AB serum (H4522 Sigma, Taufkirchen, Germany) and stored for 30 minutes at 37°C prior further use.
Cell viability, purity and activation were confirmed by microscopic examination (EVOS ® FL Cell Imaging System AMF4300, life technologies, USA). 1 μL propidium iodide was used for 10 μL cell suspension to visualize damaged or dead cells with a RFP (red fluorescent protein)
cube. Eosinophilic granulocytes were visualized by autofluorescence with a GFP (green fluorescent protein) cube. Nonautofluorescent cells were defined to be neutrophil granulocytes without separation of the basophilic fraction, considered to be lower than 1%. Neutrophilic purity was defined as (%Neutros + %Neutros dead), and neutrophilic viability was defined as 1 -(%Neutros dead/(%Neutros + %Neutros dead)). Samples with both results ≥95% were accepted.
Neutrophil activation prior to stimulation or migration was excluded by CD62L labelling (cluster of differentiation) antibody (PN IM1231U, Beckman Coulter, Krefeld, Germany). CD62L (or L-selectin) is continuously produced by neutrophils and is shed of shortly after activation. 25, 26 A loss of more than 20% of observed neutrophils was considered as a sample with premature activation and was not included in further examination.
To investigate the effect of peptide treatment on migrational behaviour, neutrophils (3*10 6 per mL in AB serum, H4522 Sigma, Taufkirchen, Germany) were preincubated for 1 hour with CP17 or SP17 at 5.0 or 50.0*10 −6 mol/L at 37°C and 5% CO 2 .
| Quantification of in vitro chemotaxis
The assay was performed as previously described. 27 In brief, for time-lapse imaging of neutrophil migration, neutrophils were placed into a μ-slide Chemotaxis 3D (IBIDI, Martinsried, Germany) and F I G U R E 1 CP17 decreases production rate of ROS. ROS production was measured by preincubating cells with indicated concentration of peptides or vehicle for 1 h. Fifty thousand neutrophils per well were then stimulated with 10 nmol/L PMA for 90 min, and accumulated chemiluminescence was measured every minute with a Luminometer (BMG Biotech, Germany). A, Accumulated amount of ROS decreases significantly with CP17 but not SP17 preincubation. Accumulated (637 s, compare Figure S1 A) relative light units (RLU) are plotted vs peptide concentrations (μmol/L). *** P < 0.001 **** P < 0.0001 CP17 vs SP17 n.s., not significant. B, Half-maximal production rate was determined from maximal ROS production rate plateau of each kinetic curve as seen in Figure S1 A. * P < 0.05, *** P < 0.001 CP17 vs vehicle; +P < 0.05, ++P < 0.01 for SP17 vs CP17, ### P < 0.001 SP17 vs vehicle, n.s., not significant. SP17 n = 6, CP17 n = 14 28 After image segmentation and tracking, each trajectory of a neutrophil granulocyte is characterized using the mean speed and the directionality.
The directionality is calculated as the displacement (distance between the start-and end-point of each trajectory) divided by the cumulative distance the neutrophil has travelled. An illustration of the migration patterns of directed and undirected cells is presented in Figure 2 A + B.
To assess the quality of the tracking results, we followed the scheme presented in Ref. 27 and calculated the valid observation time 
| Normalization of the migration parameter
Migration patterns of the neutrophils are patient-specific, and we normalized each CP17 and SP17 run against a vehicle control experiment using neutrophils from the same donor. For each patient, we calculated the mean and standard deviation of the speed and directionality of the control experiment. Next, we nor- 
| Reactive oxygen species (ROS)
Isolation of neutrophils was performed as described above. After isolation, neutrophils were counted, adjusted to 5 × 10 6 per mL and Final accumulated luminescence signal was then used for analysis.
Each condition was measured in triplicates, and mean value was used to determine amount of produced ROS. Analysis was performed by MARS software (BMG Labtech, Germany).
| Tumstatin-derived peptides
Peptides were synthesized and provided by R. Bartels (Forschungszentrum Borstel, Germany), and sequence of CP17
(VCNFASRNDYSYWLSTP) was determined as described in Weckmann et al 15 and compared with Monboisse et al. 29 Scrambled peptides were generated using RandSeq from the ExPAsy web page (http://web.expasy.org/randseq/) and blasted against human protein sequences via the blastp website (www.pubmed.com). Nonhomologous sequences were further evaluated for solubility and cell toxicity (A549 and neutrophils, propidium iodide exclusion assay). Most similar, nontoxic behaviour SP17-peptide was used for further experiments (sequence: PSFRDSAWNCYTNYLVS). CP17 dose was deducted from previous experiments (data not shown) using lipopolysaccharide stimulation.
| Animals
Female, 6-to 8-week-old C57BL/6 mouse (Charles River, Sulzfeld, Germany) were housed under specific pathogen-free conditions and received ovalbumin (OVA)-free diet and water ad libitum. All animal studies were approved by the animal ethics committee from the 
| Animal treatment protocol
Exacerbation model was established as previously described. . Each point represents one tracked neutrophil granulocyte, and the blue/green lines show the density distribution. In this representation, the inhibitory effect results in a shifted centroid of the CP17 distribution (green) compared to the vehicle distribution (blue) towards a slower and more undirected migration pattern. C, Change in directionality after CP17 treatment. Higher dose of peptides (50 μmol/L) reverses effects. D, fMLP results in stronger decrease in directionality in the low concentration but no difference in the high concentration. E, CP17 compared with SP17 reduces the speed of neutrophils in an IL-8 gradient. F, In fMLP, all doses of either CP17 or SP17 result in a strong reduction in speed. CP17 significantly reduces (compared to SP17) migration speed. Blue arrow indicates increase in speed or directionality, and red error denotes a reduction. Green labelled bars show CP17, red filled bars SP17. * P < 0.05, **<0.001, **** P < 0.0001
wt/vol in phosphate-buffered saline, PBS) on days 26, 27 and 28 in order to induce acute allergic airway inflammation. 31 An amount of 1 nmol CP17, vehicle (PBS) or scrambled peptide (SP17) was coinstilled after the OVA exposure and on days 27 and 28, followed immediately by a polyI:C stimulation on day 28. All animals were killed by cervical dislocation under deep anaesthesia on day 29.
Negative control animals were sham sensitized to PBS and subsequently challenged with OVA aerosol (PBS group).
| Bronchoalveolar lavage
Lungs 
| Lung histology
Lungs were fixed ex situ with 4% (wt/vol) paraformaldehyde (PFA) via the trachea under constant pressure for 20 minutes, ligated and stored in 4% PFA. Fixed lung tissues were embedded in paraffin.
Subsequently, 2-μm tissue sections were stained with haematoxylin and eosin (HE) or periodic acid-Schiff (PAS), respectively. Photomicrographs were recorded by a digital camera (DP-25, Olympus, Tokyo, Japan) attached to a microscope (BX-51, Olympus) at 40-fold and 100-fold magnification using Olympus cell^A software. For mucus quantification, systematic uniform random samples of the lungs were prepared according to standard methods 2 including the orientator technique. 3 The surface area of mucin-containing goblet cells (S gc ) per total surface area of airway epithelial basal membrane (S ep ) and the volume of PAS-stained epithelial mucin (V mucin ) per S ep were determined using a computer-assisted stereology toolbox (newCAST, Visiopharm, Horsholm, DK) 4,5 according to the following formulas: 
| RESULTS
| CP17 reduces predominantly intracellular reactive oxygen species
PMA-induced ROS production was measured using two substrates, luminol and lucigenin. Luminol permeates the cell membrane and detects total ROS (tROS), whereas lucigenin only reacts with extracellular ROS (eROS). 32 Using a scrambled peptide (SP17), we found no significant difference in the final amount of eROS in an end-point assay (data not shown). Kinetic analysis of the tROS production over 60 minutes revealed that tROS could be elevated by either of two entirely different kinetic patterns (Figure S1 A). We measured accumulated ROS at peak production rate (637 seconds in vehicle or medium control) and found a significant reduction in ROS with CP17 at 0.5 μmol/L (vs SP17, P < 0.0001) and 5.0 μmol/L (vs SP17, P < 0.001, Figure 1A ). This reduction resulted solely from a decreased production rate (see Figure S1 A and schematic Figure S1 B), and we therefore determined the normalized production rate at the half-maximal tROS level (for formula see methods), which is an indicator of the slower production rate. CP17 decreased neutrophil tROS production to 52.44% after incubation with 0.5 μmol/L (P < 0.05) and reached its maximal effect at 5 μmol/L (reduction to 30.40%, P < 0.001, Figure 1B ). This suggests that CP17 is a potent inhibitor of neutrophil total ROS production as measured by luminol.
We were further interested to see if other neutrophil functions such as CXCL8 (IL-8) secretion, degranulation and NETosis could be affected. CXCL8 secretion and neutrophil elastase release were stimulated with R848 (a Toll-like receptor 7/8 ligand, 33 ) in the presence of SP17 and CP17, but no significant effect on these functions was observed ( Figure S1C,D) . We also investigated the possibility of an effect on neutrophil extracellular DNA trap formation (NET) as it has been shown that ROS production plays a critical role in NET formation. [34] [35] [36] We did not observe a significant difference of NETosis after treatment with CP17 ( Figure S1 E) . These data suggest that albeit CP17-altered ROS production kinetics, neither secretion, degranulation nor NETosis are affected.
| CP17 inhibits the in vitro migration of neutrophils
To assess the in vitro inhibitory effect of CP17 on the migration of neutrophils, we used the SiMA migration assay described in. 27 In 
| CP17 reduces neutrophil influx in mouse models of asthma exacerbation
The observation of decreased neutrophil migration in vitro let us to hypothesize that CP17 would inhibit neutrophil accumulation in experimental asthma exacerbation. We chose a model previously published by Lunding et al, 31 in which a viral infection is modelled nor direct effects on A549 cell activity, 15 suggesting little effect of this peptide on epithelial cells. These data indicate that CP17 is highly specific for inhibition of neutrophilic inflammation in murine models of neutrophilic asthma and asthma exacerbation.
| DISCUSSION
The significant reduction of tumstatin in lung tissue from asthmatic patients has been suggested to contribute to the pathogenesis of this disease by allowing for increased neovascularization, eosinophil NISSEN ET AL.
| 1489 influx and mucus production. 5, 9, 10, 38 This study shows for the first time a distinct role of tumstatin (CP17) in moderating experimental asthma exacerbations by alleviating neutrophil inflammatory profiles in vitro (ROS production, migration) and in vivo and adds to the accumulating body of evidence of col IV matrikines to play a vital role in ECM-inflammatory crosstalk.
Effects of col IV NC1 domain fragments on leucocyte behaviour have been known for more than 20 years. 29, 39 Recently, the significant reduction of tumstatin in asthmatic lung biopsies has spurred further investigations by Burgess and colleagues on the exact function of tumstatin in mouse and sheep models of allergic asthma. 5, 9, 38 Tumstatin itself and various active fragments contained in it conferred significant biological activity by reducing eosinophil infiltration, reduced mucus production, decreased levels of IL-13 and VEGF and amelioration of bronchial hyperresponsiveness. 5 Tumstatin's activity on microvascularization was extensively explored in the context of tumour growth; however, little to no evidence was available for asthma exacerbations. [40] [41] [42] Here, we show that CP17, an active fragment of tumstatin, reduces the rate at which the ROS is produced. Monboisse et al 29 reported earlier that a peptide ter- Table 2) . 46 This indicates a certain capacity for these peptides to act as ROS scavengers. Secondly, and highly supportive of our initial hypothesis, the CP17-specific reduction in the ROS production rate indicates that this function is conferred in the sequence of CP17 (acting via a yet unknown receptor). In addition, our use of PMA as a strong yet artificial stimulus may further suggest that a fundamental cellular pathway might be involved. Further research is warranted to identify a possible CP17 receptor and the mechanism by which it interferes with ROS production.
Antimigratory effects of matrikines on tumour cells in vitro and in vivo are well documented. 11, 47, 48 Reports on inhibitory effects on neutrophil migration, however, are scarce. In our study, CP17 significantly decreased the directionality with which neutrophils migrated towards IL-8. This indicates that neutrophils encountering CP17 may experience a loss of sensing of the gradient or an inability to translate the gradient's signal accordingly. This is accompanied by a stark reduction in migrational speed in vitro in those neutrophils. Basal membranes of postcapillary venules and lung as well as the lamina propria are rich in col IV. 5, 49 Furthermore, it has been noted that the passage of basal membranes represents a significant hurdle for neutrophils. However, the role of col IV, proteases and col IV fragments is inconclusive (reviewed in 50). Col IV isoform 3 fragments have been shown to interfere with neutrophil function such as ROS production, and α v β 3 -integrin has been identified to be crucial for this interaction, but it is unclear if α v β 3 -integrin plays any role in interstitial migration of neutrophils. 29, 51 Limiting the scope of our work, we did not use full-length tumstatin in comparison with CP17 in our in vitro and in vivo experiments. We recombinantly produced tumstatin for previous studies 10, 15, 52 ; however, remaining endotoxin levels did not allow the direct use on neutrophils. The 17 aa sequence of CP17 is located in the protrusion region (aa 65-82) of tumstatin, 53, 54 suggesting a high likelihood of this region being an exposed epitope, as compared to the theoretical internal sequences within the folded molecule. Further research is warranted with full-length tumstatin to verify its effects on neutrophils in vitro and in vivo.
In the context of a neutrophil inflammation superimposed on an allergic airway inflammation, we observed a significant reduction in neutrophil infiltration into the lumen of the lungs after the application of CP17. In addition, the interstitial space between blood vessel and bronchus also showed a marked reduction in infiltrates. This may suggest that exogenous CP17's inhibitory effects may already be present at the level of the basal membrane of the blood vessel in vivo and offers the possibility that integrins such as α M β 2 or α 4 β 1 are binding partners of CP17. Burns et al showed that neutrophils can utilize various α-subunits (α 4 = CD49D, α 5 = DC49E) in conjunction with the β 1 -subunit for recruitment after endotoxin stimulus to the lung in vivo. 55, 56 However, we could not induce a full reduction in neutrophil infiltration. We also found in our in vitro migration assay that not all neutrophils seem to respond equally to CP17, leaving subpopulations migrate as they would normally do. This observation may point at a concept that distinct levels of maturity in circulating neutrophil populations exist. As early as 1993, LundJohansen et al 57 identified selective integrin expression on neutrophils during granulopoiesis reflective of the state of maturity.
Recently, the concept of mature neutrophil subpopulations in circulation was further investigated and detailed by Uhl and colleagues.
The group identified a distinct set of neutrophils with prolonged time in circulation, which preferentially respond to endotoxemic inflammation. 58 In their experiments, the lung accumulated over 50%
of those mature neutrophils high in CD44, α 4 β 1 and CXCL4 expression. These matured neutrophils represented a highly phagocytic population in the lung. 58 It remains unclear if CP17 has a specific effect on this aged group of neutrophils and what consequence would arise from their inhibition. Further research is required to understand the exact mechanism of CP17 on migrating neutrophils.
In conclusion, we characterized a 17 aa fragment (CP17) of the noncollagenous domain 1 of col IV α 3 (tumstatin) in vitro and in vivo. CP17 reduced the production rate of intracellular ROS and significantly reduced migrational speed in a μ-fluidic migration assay.
In a mouse model of asthma exacerbation, CP17 selectively inhibited neutrophil accumulation in the lung interstitium and lumen. CP17 as part of the interstitial ECM may therefore represent an endogenous tissue-specific modulator of neutrophil infiltration, balancing chemotactic drive and repulsion. The diminished levels of tumstatin observed in asthmatic individuals may increase susceptibility of asthmatics to aggravated neutrophil inflammation after viral exacerbation, contributing to more severe neutrophilic asthma phenotypes.
Furthermore, CP17 may serve as a potential precursor for drug development to combat overwhelming neutrophil inflammation and thus detrimental effects on lung or tissue remodelling in general.
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